ArticleBMC cancer2025
Syntaxin-7 promotes EMT and tumor progression via NF-κB signaling and is associated with macrophage infiltration: pan-cancer analysis and experimental validation in hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSyntaxin-7 (STX7), a membrane trafficking-related gene, has been implicated in various cancers, but its specific role in hepatocellular carcinoma remains unclear. There has been no pan-cancer analysis examining the immunological function and prognostic significance of STX7 so far.
methodsWe chose STX7 for an in-depth investigation to explore its expression patterns, prognostic significance, enriched pathways, and immune infiltration across various cancers. The transcriptional landscape of STX7 was examined at both single-cell and spatial levels, and a combination of in vitro and in vivo experiments was conducted to further validate its functional roles.
resultsSTX7 was significantly upregulated in a wide range of cancer types and was associated with poor prognosis. Additionally, STX7 was correlated with immune cell infiltration and key immune regulators. Enrichment analysis further underscored the potential role of STX7 in immune evasion and tumor progression. Single-cell and spatial transcriptome analyses revealed its specific expression in macrophages. Functional experiments demonstrated that STX7 knockout suppressed hepatocellular carcinoma proliferation and migration, while inhibiting epithelial-mesenchymal transition (EMT) via NF-κB signaling.
conclusionSTX7 promotes EMT and tumor progression via NF-κB signaling, with a strong association to macrophage infiltration in cancers, including hepatocellular carcinoma, highlighting its potential as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.